Top Page
Canopy Growth
(NASDAQ:WEED)
Canopy Growth (WEED) vs. iShares MSCI Canada ETF (EWC)
Canopy Growth Business Overview & Revenue Model
Canopy Growth Earnings Call Summary
Canopy Growth Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 278.61M | 269.00M | 297.15M | 333.25M | 510.32M | 546.65M |
| Gross Profit | 74.58M | 79.51M | 80.88M | -98.38M | -143.60M | 66.96M |
| EBITDA | -294.03M | -479.31M | -312.83M | -2.88B | -52.98M | -1.55B |
| Net Income | -385.85M | -598.12M | -657.27M | -3.28B | -310.04M | -1.74B |
Balance Sheet | ||||||
| Total Assets | 1.07B | 917.70M | 1.30B | 2.44B | 5.62B | 6.82B |
| Cash, Cash Equivalents and Short-Term Investments | 298.06M | 131.47M | 203.46M | 782.60M | 1.37B | 2.30B |
| Total Debt | 254.57M | 348.40M | 668.00M | 1.31B | 1.50B | 1.58B |
| Total Liabilities | 333.82M | 430.49M | 799.82M | 1.68B | 1.98B | 3.20B |
| Stockholders Equity | 736.01M | 487.21M | 500.37M | 758.43M | 3.59B | 3.48B |
Cash Flow | ||||||
| Free Cash Flow | -96.14M | -177.03M | -285.95M | -568.10M | -593.92M | -639.87M |
| Operating Cash Flow | -88.43M | -165.75M | -281.95M | -557.55M | -545.81M | -465.73M |
| Investing Cash Flow | 229.00K | -47.79M | 241.59M | 433.38M | 230.82M | -884.11M |
| Financing Cash Flow | 148.40M | 148.66M | -465.06M | -19.69M | -45.53M | 1.26B |
Canopy Growth Technical Analysis
Canopy Growth Risk Analysis
Canopy Growth Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | C$1.42B | 29.60 | 3.34% | ― | 22.20% | ― | |
64 Neutral | $195.25M | 4.23 | 31.46% | ― | 27.38% | ― | |
59 Neutral | C$307.61M | 75.33 | 1.86% | ― | 38.86% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$343.85M | -1.68 | -43.99% | ― | -11.16% | -29.56% | |
49 Neutral | C$359.50M | ― | -10.76% | ― | 23.87% | -19.57% | |
43 Neutral | C$589.53M | ― | -60.19% | ― | -0.67% | 58.98% |
Canopy Growth Corporate Events
Canopy Growth has launched the Claybourne Gassers, a new line of All-in-One vapes featuring liquid diamonds, in Canada. This launch marks Claybourne’s entry into the Canadian vape market, enhancing its presence in the high-growth vape segment. The new products, which include high-THC vapes and infused pre-rolls, are designed to meet the rising consumer demand for potent and flavorful cannabis products. This expansion is expected to strengthen Canopy Growth’s market position and cater to the accelerating demand in the adult-use cannabis market.
Canopy Growth has expanded its Spectrum Therapeutics portfolio in Australia by introducing new softgel capsules, enhancing its medical cannabis offerings in the region. This expansion strengthens Canopy Growth’s presence in the maturing Australian market, providing patients with more choices and supporting the company’s global medical strategy.
Canopy Growth reported a significant improvement in its financial performance for the second quarter of fiscal 2026, with a notable increase in Canada adult-use and medical cannabis revenues. The company’s disciplined cost management and strategic focus have resulted in a stronger balance sheet, resolving previous concerns about its ability to continue as a going concern. Despite challenges in international markets and a decrease in revenue from its Storz & Bickel segment, the company has managed to reduce its operating loss and improve its adjusted EBITDA. This financial progress positions Canopy Growth for sustained growth and resilience in the competitive cannabis industry.
Canopy Growth Corporation will announce its second quarter fiscal year 2026 financial results on November 7, 2025. The announcement will be followed by an audio webcast featuring CEO Luc Mongeau and CFO Tom Stewart. This release is significant as it provides insights into the company’s financial health and strategic positioning in the cannabis industry, potentially impacting stakeholders and market perceptions.
Canopy Growth has announced that its DOJA facility in Kelowna, British Columbia, will now exclusively produce craft cannabis for the Spectrum Therapeutics medical portfolio in Canada. This move underscores Canopy Growth’s commitment to the medical cannabis market and aims to strengthen its position by focusing on high-quality, small-batch production for registered medical patients, including veterans.
Canopy Growth Corporation has adjourned its Annual General and Special Meeting of Shareholders due to a lack of quorum and will reconvene on October 10. The company is actively encouraging shareholders to vote before the new meeting date to ensure quorum is met, which is a requirement for its NASDAQ listing. This adjournment allows shareholders additional time to participate in the decision-making process, potentially impacting the company’s governance and future strategies.
Canopy Growth has extended the proxy voting deadline for its upcoming annual general and special meeting to ensure a quorum is achieved. The extension aims to give shareholders more time to vote, as the company is close to reaching the required quorum for the meeting, which is crucial for transacting business.
Canopy Growth is urging its shareholders to vote in the upcoming annual general and special meeting to help reach the quorum needed to avoid delays and additional costs. The company emphasizes the importance of shareholder participation, regardless of the number of shares owned, to meet the NASDAQ listing requirements and ensure the meeting proceeds as planned.
Canopy Growth has appointed Tom Stewart as Chief Financial Officer to strengthen its operational discipline and financial stability. His leadership is expected to drive performance improvements and support the company’s fiscal year 2026 strategy, focusing on structural efficiency and disciplined capital management.
Canopy Growth has made an early prepayment of US$25 million on its senior secured term loan, completing its obligation under an agreement with lenders. This move is expected to reduce the company’s annual cash interest expense by US$6.5 million, strengthening its financial position and reflecting its strategic focus on debt reduction.
Canopy Growth Corporation announced the early prepayment of a US$25 million term loan, completing an aggregate of US$50 million in prepayments under an agreement with its lenders. This financial move is expected to reduce the company’s annual cash interest expense by US$6.5 million, thereby strengthening its financial position and demonstrating prudent fiscal management. The accelerated debt reduction is part of Canopy Growth’s strategy to enhance its financial stability and operational efficiency, potentially benefiting stakeholders by improving the company’s market positioning.
STORZ & BICKEL, a subsidiary of Canopy Growth Corporation, has launched the VEAZY, a compact and accessible vaporizer, expanding its premium product portfolio. The VEAZY, available in four colors, offers portability, style, and high performance at a competitive price, aiming to reach a broader audience and enhance the company’s market presence in over 100 countries.